Table 1 Outcome with different treatment... | American Society of Hematology

Table 1

Outcome with different treatment approaches in older patients with ALL

Approach	Age range (y)	No. of studies	No. of patients	CR (range) (%)*	Early death (range) (%)*	Survival (range) †
Approach	Age range (y)	No. of studies	No. of patients	CR (range) (%)*	Early death (range) (%)*	%	Months
Population-based studies^1,11,40,42	>65	4	N/R	40⁴⁹	N/R	6-30
Palliative treatment^4,5,41,43	60-91	4	94	43 (34-53)	24 (18-42)		7 (3-10)
Intensive chemotherapy designed for adult ALL without focus on older patients^{6,14,15,38,39,44-50}	60-92	12	519	56 (40-81)	23 (6-42)	14 (3-29)
Prospective studies for older ALL patients‡^13,14,51-56	55-81	9	447	71 (43-90)	15 (0-36)	33 (16-71)

Approach	Age range (y)	No. of studies	No. of patients	CR (range) (%)*	Early death (range) (%)*	Survival (range) †
Approach	Age range (y)	No. of studies	No. of patients	CR (range) (%)*	Early death (range) (%)*	%	Months
Population-based studies^1,11,40,42	>65	4	N/R	40⁴⁹	N/R	6-30
Palliative treatment^4,5,41,43	60-91	4	94	43 (34-53)	24 (18-42)		7 (3-10)
Intensive chemotherapy designed for adult ALL without focus on older patients^{6,14,15,38,39,44-50}	60-92	12	519	56 (40-81)	23 (6-42)	14 (3-29)
Prospective studies for older ALL patients‡^13,14,51-56	55-81	9	447	71 (43-90)	15 (0-36)	33 (16-71)

N/R, not reported.

Weighted means and range from cited studies for CR rates, early death rates, and survival.

†

Weighted means and ranges for survival probability at 2 or more years, as reported in the cited studies, or median survival time and ranges, respectively.

‡

Details are given in Table 2.

View Large

This Feature Is Available To Subscribers Only